Cargando…

Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants

Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5, CH.1.1, and CA.3.1, as well as their impacts on spike protein biol...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Panke, Faraone, Julia N., Evans, John P., Zheng, Yi-Min, Carlin, Claire, Anghelina, Mirela, Stevens, Patrick, Fernandez, Soledad, Jones, Daniel, Panchal, Ashish, Saif, Linda J., Oltz, Eugene M., Xu, Kai, Gumina, Richard J., Liu, Shan-Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882202/
https://www.ncbi.nlm.nih.gov/pubmed/36711991
http://dx.doi.org/10.1101/2023.01.16.524244
_version_ 1784879254087925760
author Qu, Panke
Faraone, Julia N.
Evans, John P.
Zheng, Yi-Min
Carlin, Claire
Anghelina, Mirela
Stevens, Patrick
Fernandez, Soledad
Jones, Daniel
Panchal, Ashish
Saif, Linda J.
Oltz, Eugene M.
Xu, Kai
Gumina, Richard J.
Liu, Shan-Lu
author_facet Qu, Panke
Faraone, Julia N.
Evans, John P.
Zheng, Yi-Min
Carlin, Claire
Anghelina, Mirela
Stevens, Patrick
Fernandez, Soledad
Jones, Daniel
Panchal, Ashish
Saif, Linda J.
Oltz, Eugene M.
Xu, Kai
Gumina, Richard J.
Liu, Shan-Lu
author_sort Qu, Panke
collection PubMed
description Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5, CH.1.1, and CA.3.1, as well as their impacts on spike protein biology. Our results demonstrated a nearly complete escape of these variants from neutralizing antibodies stimulated by three doses of mRNA vaccine, but neutralization was rescued by a bivalent booster. However, CH.1.1 and CA.3.1 variants were highly resistant to both monovalent and bivalent mRNA vaccinations. We also assessed neutralization by sera from individuals infected during the BA.4/5 wave of infection and observed similar trends of immune escape. In these cohorts, XBB.1.5 did not exhibit enhanced neutralization resistance over the recently dominant BQ.1.1 variant. Notably, the spike proteins of XBB.1.5, CH.1.1, and CA.3.1 all exhibited increased fusogenicity compared to BA.2, correlating with enhanced S processing. Overall, our results support the administration of new bivalent mRNA vaccines, especially in fighting against newly emerged Omicron subvariants, as well as the need for continued surveillance of Omicron subvariants.
format Online
Article
Text
id pubmed-9882202
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-98822022023-01-28 Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants Qu, Panke Faraone, Julia N. Evans, John P. Zheng, Yi-Min Carlin, Claire Anghelina, Mirela Stevens, Patrick Fernandez, Soledad Jones, Daniel Panchal, Ashish Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu bioRxiv Article Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5, CH.1.1, and CA.3.1, as well as their impacts on spike protein biology. Our results demonstrated a nearly complete escape of these variants from neutralizing antibodies stimulated by three doses of mRNA vaccine, but neutralization was rescued by a bivalent booster. However, CH.1.1 and CA.3.1 variants were highly resistant to both monovalent and bivalent mRNA vaccinations. We also assessed neutralization by sera from individuals infected during the BA.4/5 wave of infection and observed similar trends of immune escape. In these cohorts, XBB.1.5 did not exhibit enhanced neutralization resistance over the recently dominant BQ.1.1 variant. Notably, the spike proteins of XBB.1.5, CH.1.1, and CA.3.1 all exhibited increased fusogenicity compared to BA.2, correlating with enhanced S processing. Overall, our results support the administration of new bivalent mRNA vaccines, especially in fighting against newly emerged Omicron subvariants, as well as the need for continued surveillance of Omicron subvariants. Cold Spring Harbor Laboratory 2023-01-17 /pmc/articles/PMC9882202/ /pubmed/36711991 http://dx.doi.org/10.1101/2023.01.16.524244 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Qu, Panke
Faraone, Julia N.
Evans, John P.
Zheng, Yi-Min
Carlin, Claire
Anghelina, Mirela
Stevens, Patrick
Fernandez, Soledad
Jones, Daniel
Panchal, Ashish
Saif, Linda J.
Oltz, Eugene M.
Xu, Kai
Gumina, Richard J.
Liu, Shan-Lu
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
title Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
title_full Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
title_fullStr Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
title_full_unstemmed Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
title_short Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
title_sort extraordinary evasion of neutralizing antibody response by omicron xbb.1.5, ch.1.1 and ca.3.1 variants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882202/
https://www.ncbi.nlm.nih.gov/pubmed/36711991
http://dx.doi.org/10.1101/2023.01.16.524244
work_keys_str_mv AT qupanke extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT faraonejulian extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT evansjohnp extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT zhengyimin extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT carlinclaire extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT anghelinamirela extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT stevenspatrick extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT fernandezsoledad extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT jonesdaniel extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT panchalashish extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT saiflindaj extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT oltzeugenem extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT xukai extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT guminarichardj extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants
AT liushanlu extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants